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Impulse oscillometry identifies peripheral
airway dysfunction in children with
adenosine deaminase deficiency
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Dean D. Metcalfe1† and Fabio Candotti2,6†
Abstract
Adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) is characterized by
impaired T-, B- and NK-cell function. Affected children, in addition to early onset of infections, manifest
non-immunologic symptoms including pulmonary dysfunction likely attributable to elevated systemic
adenosine levels. Lung disease assessment has primarily employed repetitive radiography and effort-dependent
functional studies. Through impulse oscillometry (IOS), which is effort-independent, we prospectively obtained
objective measures of lung dysfunction in 10 children with ADA-SCID. These results support the use of IOS in the
identification and monitoring of lung function abnormalities in children with primary immunodeficiencies.
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Background
Children with primary immunodeficiency diseases
(PIDs) often suffer from severe and life-threatening
illnesses. Adenosine deaminase (ADA) deficiency is
among the most severe forms of PIDs, leading to
severe combined immunodeficiency (SCID) and sus-
ceptibility to severe and recurrent opportunistic
infections. In addition, the ubiquitous expression of
ADA confers additional clinical phenotypes to
patients affected with ADA-SCID that include non-
infectious abnormalities of the lung that are incom-
pletely characterized [1, 2]. Assessment of lung dis-
ease in children may employ X-ray and conventional
tomography imaging, while lung function is usually
evaluated using spirometry, which is effort-dependent
and thus difficult to perform in younger patients.
Impulse oscillometry (IOS) has been suggested as an
alternative technique to assess lung function with a
particular application to younger children and others
unable to perform spirometry [3–5]. IOS is best under-
stood as a technique that generates small pressure oscilla-
tions that are applied at the mouth and transmitted into
the lungs, which in turn enables the measurement of
resistance and reactance to the impedance of the respira-
tory system during spontaneous quiet breathing, and
therefore provides an indirect quantification of lung
function.
Findings
Subject characteristics
We assessed lung function in 10 children (3–18 years
of age) with ADA-SCID by IOS and spirometry fol-
lowing informed consent. Seven patients were on
treatment with PEG-ADA and 3 with gene therapy.
Six patients had undergone CT imaging of their lungs
and displayed: diffuse ground glass opacities (n = 3),
parenchymal cysts (n = 2), mosaic attenuation (n = 4),
bronchiectasis (n = 1), and nodules (n = 1). All patients
could perform IOS while only 5 patients were able to
complete spirometry (Table 1). In addition, 82 control
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subjects of ages 4–18 were evaluated following informed
consent. Details regarding methodology, demographics,
disease presentation, ADA activity, pulmonary and im-
mune status are shown in Additional file 1: Table S1.
Pulmonary function measurements
Patient characteristics did not differ significantly when
subdividing the entire cohort (n = 10) into patients
that could (n = 5) and could not (n = 5) perform
spirometry (due to intellectual or physical disability)
and in comparison to age matched healthy controls
(n = 82, Table 2). The mean baseline measurements of
patients with ADA-SCID were within the normal
range for spirometry and IOS (Table 3). With the
exception of a higher expiratory peak flow (PEF), on
average, ADA-SCID patients showed spirometry
results similar to healthy controls (Table 3). IOS test-
ing, however, revealed that the ADA-SCID patient
cohort presented significant increases in baseline
percent-predicted values for resistance at 5 Hz (R5,
p = 0.032; Student t-test), and 10 Hz (R10, p = 0.044;
Student t-test). Peripheral airway reactance was also
significantly increased as indicated by higher X values
at 5 Hz (X5, p = 0.001, data summarized in Fig. 1a)
and change in X5 from reference (X5ref-X5, p = 0.041;
Table 3, italicized values). Although, as a group, the
R5-R20(%) of ADA-SCID patients did not differ sig-
nificantly from control subjects, 4 patients had abnor-
mal values (>35 %). Thus, patients with ADA-SCID
displayed measurable defects in peripheral airway that
was detected by IOS and not spirometry. A more
detailed analysis focusing on individual patients re-
vealed that 2 out of 5 patients who completed
spirometry (based on FEV1) and 7 out of 10 patients
who underwent IOS (based on R5, R5-R20% and
X5ref-X5) had abnormal baseline pulmonary function
(Additional file 1: Table S2).
After bronchodilator administration, the mean re-
sponse in ADA-SCID patients was within the normal
range for both spirometry and IOS, except for an
improved mean ΔR10 of −15.4 %, indicating borderline
airways hyperreactivity (cutoff −15 %, Table 4, Fig. 1b).
An individual analysis of the 4 patients that underwent
post-bronchodilator spirometry revealed that none of
the patients displayed reversibility (FEV1 cutoff, 12 %
change). However, IOS testing was able to detect
Table 1 Patient characteristics and pulmonary imaging and function testing
UPN Age (years) Gender Ethnicitya Treatmentb CT Spirometry IOS
1-ADA26 3 F C 1 ND - +
2-ADA41 5 F C 2 ND - +
3-ADA14 8 F C 2 Normal + +
4-ADA16 9 M H 1 dGGO, MA, B - +
5-ADA18 10 F A 2 ND + +
6-ADA5 12 M AA 1 MA + +
7-ADA46 14 F C 2 dGGO, PC, MA, N - +
8-ADA17 16 F AA 2 MA - +
9-ADA3 17 M C 2 dGGO, PC + +
10-ADA47 18 M AA 2 ND + +
aC = Caucasian, H = Hispanic, A = Asian, AA = African American
b1 = Gene Therapy; 2 = ADA conjugated with polyethylene glycol (PEG-ADA)
CT findings: ND CT not performed, dGGO diffuse ground glass opacities, PC parenchymal Cysts, MA Mosaic attenuation, B Bronchiectasis, N Nodules
+ Indicates successful completion of Spirometry and/or IOS
Table 2 Pulmonary function testing in patients vs. controls
Characteristics IOS (n = 10) Spirometry able (n = 5) IOS and not Spirometry (n = 5) Controls (n = 82) aP value (t-test)
Age mean (SD) 11.2 (5.1) 13.0 (4.6) 9.4 (5.3) 9.22 (3.21) 0.090
Female Gender, n (%) 6 (60) 2 (40) 4 (80) 34 (41) 0.332
Height (cm) 135.9 (25.7) 146.3 (27.2) 125.5 (21.9) 136.22 (17.16) 0.957
Weight (kg) 44.3 (26.8) 54.6 (30.5) 33.9 (20.4) 39.64 (28.68) 0.630
acomparison of IOS (n = 10) to Controls
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significant reversible obstruction in half of the cohort,
including 2 of the 4 patients who did not show revers-
ibility by spirometry (Additional file 1: Table S2).
Thus, in a cohort of 10 children with ADA-SCID, IOS
was easily employed to assess dynamic lung function; while
half of the patients could not complete spirometry testing.
Baseline abnormality of pulmonary resistance (R) and react-
ance (X) was detected in the majority of ADA-SCID
patients (70 %) using IOS. Undiagnosed reversible airway
disease was revealed in half of the patients and only when
using IOS. Also, in comparison to a pediatric control group
of 82 patients, statistically significant abnormalities of
peripheral airways were detected as indicated by measure-
ment of airway resistance and reactance at lower frequen-
cies (R5, R10, and X5).
Discussion
Adenosine deaminase deficiency causes bronchial
inflammation, pulmonary fibrosis and alveolar enlarge-
ments in Ada knockout mice [6–8]. Similarly, non-
infectious lung abnormalities are emerging as frequent
complications in patients with ADA-SCID. In prior
reports, these abnormalities appeared to resolve upon
enzyme replacement or transplantation [1, 2]. However,
our results provide clinical evidence of continuing
peripheral airway dysfunction in a significant fraction of
patients receiving treatment resulting in sufficient cor-
rection of their immune function. These findings sug-
gest that current therapeutic approaches such as ERT
and gene therapy may be insufficient in preventing or
controlling lung complications in ADA-SCID. Whether
this is also the case of hematopoietic stem cell transplant-
ation [9] remains to be investigated. Our IOS data indi-
cates clinical evidence of continuing peripheral airway
dysfunction in a significant fraction of patients that
received treatment resulting in improvement of their
immune function. The majority of patients with persistent
lung disease (pneumonias, bronchiectasis) had abnormal
findings on IOS. These observations appear to be inde-
pendent of age and dAXP levels of diagnosis, and type of
therapy employed (enzyme replacement or gene therapy).
There were no correlations between the presence of lung
abnormalities and demographics, therapeutic, and im-
munological parameters, however, we recognize that the
small number of patients studied may have limited the
ability to detect the effects of such variables. However, we
believe it is important to caution care providers that
ADA-SCID patients may benefit from therapies that target
peripheral airway inflammation like inhaled corticoste-
roids and leukotriene inhibitors [10]. The long-term clin-
ical significance in lung abnormalities in ADA-SCID
patients is unknown, but our observations support the use
of IOS for the identification and monitoring of this com-
plication in children with this and other primary
immunodeficiencies.
Additional file
Additional file 1: Online Supplementary Material. Table S1. ADA-
SCID patient cohort characteristics. Table S2. Baseline and Reversibility.
(DOCX 75 kb)
Table 3 Baseline results in patients vs. controls
Baseline Measurements
Mean (SD) P value (T-test) aMean % Reference (SD) P value (t-test)
Spirometry Patients n = 5 Controls n = 82 Patients n = 5 Controls n = 82
FEV1 (L) 2.2 (1.0) 1.85 (0.7) 0.354 86.0 (8.2) 90.8 (22.4) 0.636
FVC (L) 2.5 (1.2) 2.28 (0.9) 0.576 89.8 (11.8) 100.7 (17.6) 0.178
FEV1/FVC (%) 86.8 (3.4) 82.0 (9.9) 0.282
PEF (L/sec) 6.2 (3.6) 4.0 (1.6) 0.007 104.8 (25.5) 95.1(25.8) 0.418
Impulse oscillometry Patients n = 10 Controls n = 82 Patients n = 10 Controls n = 82
R5 (cmH20/L/sec) 8.4 (3.3) 7.8 (2.3) 0.488 122.3 (33.3) 103.4 (24.7) 0.032
R10 (cmH20/L/sec) 6.9 (2.5) 6.4 (1.7) 0.451 112.3 (33.9) 95.9 (22.4) 0.044
R20 (cmH20/L/sec) 5.7 (1.9) 5.4 (1.3) 0.592 98.0 (27.0) 93.8 (22.5) 0.592
R5-R20 (%)Δ 30.6 (9.4) 29.6 (11.0) 0.780
X5 (cmH20/L/sec) −3.6 (1.8) −3.0 (1.3) 0.231 182 (78.7) 118.7 (50) 0.001
AX (cmH20/L) 27.5 (21.6) 22.4 (14.6) 0.323
Fres Hz 22.2 (6.3) 20.5 (4.4) 0.280
X5ref-X5 (cmH20/L/sec) 1.3 (1.2) 0.35 (1.3) 0.041
aNormal cut-off: Spirometry >80 % Reference; IOS: R5, R10, R20, <140 % Ref, X5ref-X5 < 1.5 cm H20/L/sec,
ΔR5-R20 < 35 %
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Fig. 1 Baseline and Post bronchodilator Response. The mean % predicted values of all control subjects and patients with ADA-SCID as
determined by spirometry and IOS is displayed at baseline (a) and the mean change of the bronchodilator response (b) with significance
noted in baseline values for R5, R10 and X5 (p value; * < 0.05, ** <0.005)
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Abbreviations
ADA-SCID: Adenosine deaminase deficient severe combined immunodeficiency;
IOS: Impulse Oscillometry; FVL: Flow-volume loop; PFTs: Pulmonary function tests;
ERS/ATS: European respiratory society/American thoracic society; Z: Impedance;
R: Resistance; X: Reactance; Hz: Hertz.
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Table 4 Bronchodilator response in patients vs. controls
Bronchodilator
responsea
Mean % change
(SD)
P value
(T-test)
Spirometry Patients n = 4 Controls n = 82
ΔFEV1 3.3 (4.7) 5.5 (9.7) 0.607
ΔFVC 1.3 (6.5) 2.7 (7.0) 0.341
ΔFEV1 / FVC 2.5 (4.6) 4.3 (8.1) 0.672
ΔPEF −4.5 (13.7) 6.5 (15.5) 0.164
Impulse oscillometry Patients n = 10 Controls n = 82
ΔR5 −15.3 (15.9) −14.6 (12.0) 0.438
ΔR10 −15.4 (12.5) −14.5 (10.7) 0.809
ΔR20 −12.6 (11.1) −9.6 (12.7) 0.483
ΔR5-R20 −8.5 (28.7) −11.7 (29.8) 0.745
ΔX5 −18.2 (31.9) −14.7 (24.0) 0.673
ΔAX −21.6 (29.7) −33.3(22.6) 0.139
ΔFres −13.4 (15.8) −13.1 (20.9) 0.961
aAirway reversibility was considered evident when there was an improvement
in any of the following bronchodilator parameters : ΔR5≥ −20 %, ΔR10 ≥ −15 %,
ΔR20 ≥ −20 %, ΔAX ≥ −45 %, and ΔFres≥ −25 %. By design, the percent
improvement (reversibility) is displayed as a negative number because it
indicates a magnitude decrease in resistance or reactance
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